White House economists have projected that President Donald Trump's agreements with pharmaceutical companies to lower U.S. prescription drug prices to levels comparable to those in other affluent nations could result in $529 billion in savings over the next decade. This analysis, conducted by the White House Council of Economic Advisers, is part of Trump's strategy as he approaches the midterm elections, where cost-of-living issues are a major concern for voters. The report also estimates that federal and state governments could save $64.3 billion on Medicaid due to Trump's 'most favoured nation' policy. However, Democratic lawmakers have expressed skepticism about these savings, questioning the lack of transparency surrounding the deals. They argue that any potential reductions in drug prices may be offset by increased costs for drugs not included in the pricing framework. The analysis further suggests that Americans are projected to spend $467 billion on prescription drugs in 2024, emphasizing the importance of these savings. Critics, including Senator Bernie Sanders' staff, have pointed out that the profits of pharmaceutical companies involved in these agreements have surged by 66% over the past year, raising concerns about the effectiveness of the administration's approach to drug pricing.